Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020-2026
|出版商||Frost & Sullivan||商品編碼||954127|
|出版日期||內容資訊||英文 71 Pages
|通過戰略業務合作關係改變全球生物銀行市場（2020-2026） Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020-2026|
|出版日期: 2020年08月12日||內容資訊: 英文 71 Pages|
Precision Medicine Applications and Value-based Data Pricing with Pharma and Health-tech to Trigger Market Growth
The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research. This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies.
The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future. Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. A number of leading biobanks in the United States, the United Kingdom, Sweden, and Denmark have taken major strides in adopting and implementing industry best practices in the last few years.